Medtronic unveils adaptive deep brain stimulation trial in Parkinson s patients
Medtronic unveils adaptive deep brain stimulation trial in Parkinson s patients
15 January 2021 | News The randomised study will take place across 12 study sites at leading movement disorders research centers in the US, Europe, and Canada
Source: medtronic.com
Medtronic plc, the global leader in medical technology, announced the first enrolment in ADAPT-PD (Adaptive DBS Algorithm for Personalised Therapy in Parkinson s Disease), its trial evaluating the safety and efficacy of adaptive deep brain stimulation (aDBS) in patients with Parkinson s Disease (PD). Adaptive deep brain stimulation is an investigational feature of the Percept™ PC device that could be enabled if approved.
Parkinson s
Disease), its trial evaluating the safety and efficacy of adaptive deep brain stimulation (aDBS) in patients with Parkinson s Disease (PD). Adaptive deep brain stimulation is an investigational feature of the Percept™ PC device that could be enabled if approved. The investigational feature used in this study allows for automated adjustment of brain stimulation to provide therapy to manage symptoms of Parkinson s disease based on a patient s clinical state.
The randomized study will take place across 12 study sites at leading Movement Disorders research centers in the United States, Europe, and Canada. An estimated 36 subjects will undergo a total evaluation period of 15 months. The primary endpoint of ADAPT-PD will compare standard continuous DBS (cDBS) to aDBS for hours of On time without troublesome dyskinesias, a measure of treatment efficacy versus side effects, as reported by patient diary. Qualifying subjects in the study will receive cDBS at baseline follo